Contentious Indian Pricing Orders Now In Court
This article was originally published in Scrip
A string of controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA) are believed to have been challenged in court, putting plans to enforce these rules in limbo, at least in specific cases.
You may also be interested in...
The Bombay High Court has stayed certain controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA), including one pertaining to transitioning "non-scheduled" medicines, as the pharmaceutical industry contests multiple regulatory changes in India.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.